Parkinsons disease (PD) is a progressive neurodegenerative disease with substantial and
growing socio‐economic burden. In this multifactorial disease, aging, environmental, and …

Background: Objectively measuring Parkinson's disease (PD) signs and symptoms over time
is critical for the successful development of treatments aimed at halting the disease …

In drug development, pharmacometric approaches consist in identifying via a model
selection (MS) process the model structure that best describes the data. However, making …

Use of early predictive biomarkers of neurodegenerative disease in phase I clinical trials
may improve the translation of novel drug therapies from preclinical development through …

Background Longitudinal item response theory (IRT) models previously suggested that the
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) motor …

Background In PD, tremor severity behaves differently from other core motor features.
However, the most commonly used assessment of overall motor severity, total MDS‐UPDRS …

Background and Objectives REM sleep behavior disorder (RBD) is a parasomnia
characterized by dream enactment. The International RBD Study Group developed the RBD …

Composite assessments aim to combine different aspects of a disease in a single score and
are utilized in a variety of therapeutic areas. The data arising from these evaluations are …

Degenerative cerebellar ataxias comprise a heterogeneous group of rare and ultra‐rare
genetic diseases. While disease‐modifying treatments are now on the horizon for many …

Abstract The Movement Disorder Society revised version of the Unified Parkinson's Disease
Rating Scale (MDS‐UPDRS) parts 2 and 3 reflect patient‐reported functional impact and …